Adjuvant nitrosourea therapy for glioblastoma.
Arch Neurol
; 33(11): 745-50, 1976 Nov.
Article
em En
| MEDLINE
| ID: mdl-985152
ABSTRACT
An attempt was made to evaluate the potential advantages of chemotherapy in the treatment of 62 patients with glioblastoma. Twenty-four of the 62 patients received adjuvant nitrosourea chemotherapy with carmustine (BCNU), lomustine (CCNU), or semustine (methyl CCCNU) in addition to surgery and radiotherapy. Thirty-three of the 62 patients were involved in a controlled, prospective, randomly allocated study. Quality or quantity of survival was not prolonged in patients who received chemotherapy. Age greater than 64 years, a severe postoperative neurological deficit, or the onset of symptoms less than 12 months prior to surgery were associated with a worse prognosis. The valid evaluation of the effect of a form of treatment on survival in patients with glioblastoma is contingent on the regorous avoidance of preselected factors that may predispose the treated group to a more favorable prognosis.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Semustina
/
Neoplasias Encefálicas
/
Carmustina
/
Glioma
/
Lomustina
/
Compostos de Nitrosoureia
Tipo de estudo:
Clinical_trials
/
Prognostic_studies
Limite:
Adolescent
/
Adult
/
Aged
/
Child
/
Child, preschool
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Arch Neurol
Ano de publicação:
1976
Tipo de documento:
Article